Versant Venture Capital VI, L.P. 4
4 · LENZ Therapeutics, Inc. · Filed Oct 2, 2025
Insider Transaction Report
Form 4
Versant Venture Capital VI, L.P.
10% Owner
Transactions
- Sale
Common Stock
2025-09-30$45.35/sh−49,701$2,254,174→ 1,133,842 total - Sale
Common Stock
2025-09-30$45.35/sh−34,405$1,560,428→ 821,752 total(indirect: See Footnote) - Sale
Common Stock
2025-09-30$46.41/sh−83,066$3,854,827→ 1,050,776 total - Sale
Common Stock
2025-09-30$47.01/sh−123$5,783→ 764,127 total(indirect: See Footnote) - Sale
Common Stock
2025-09-30$47.01/sh−177$8,321→ 1,050,599 total - Sale
Common Stock
2025-09-30$46.41/sh−57,502$2,668,484→ 764,250 total(indirect: See Footnote)
Holdings
- 842,162(indirect: See Footnote)
Common Stock
Footnotes (6)
- [F1]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $45.00 to $45.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
- [F2]These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
- [F3]These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
- [F4]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.00 to $46.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
- [F5]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $47.00 to $47.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.
- [F6]These shares are held by Versant Vantage II, L.P. ("VV II"). Versant Vantage II GP-GP, LLC ("VV II GP-GP") is the sole general partner of Versant Vantage II GP, L.P. ("VV II GP") and VV II GP is the sole general partner of VV II. Each of VV II GP-GP and VV II GP may be deemed to share voting, investment and dispositive power over the shares held by VV II and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.